摘要
癫癎是一种由不同原因引起的慢性脑部疾患,目前临床抗癫癎药物(AEDs)种类繁多,但仍有约30%癫癎患者癎性发作不能控制,需多种AEDs联合应用或加用新的AEDs。新的AEDs应具有好的临床效能、耐受性及药代动力学和最小的不良反应。目前新一代AEDs包括20种,大多为现有AEDs的衍生物,其中Brivaracetam(BRI)为左乙拉西坦(LEV)的衍生物。本文将从LEV及其衍生物BRI的作用机制、临床应用、耐受性、药理及毒理、不良反应等方面对AEDs发展趋势作一综述。
Epilepsy is a chronic neurological disorder with different etiologies.Despite of many antiepileptic drugs（AEDs） used in clinical treatment,about 30% of the patients have uncontrolled onset,and combined use of different AEDs or new AEDs are needed.The new AEDs should have satisfactory clinical efficacy,tolerability and pharmacokinetic properties,and minimal adverse effects.By now there have been about 20 novel AEDs;most of them are derivatives or analogues of current AEDs.Brivaracetam（BRI） is the derivative of levetiracetam（LEV）.This review summarizes the mechanisms of action,pharmacokinetic profiles,tolerability,pharmacology and toxicology,and side effects of LEV and its derivative BRI.
出处
《第二军医大学学报》
CAS
CSCD
北大核心
2011年第5期550-553,共4页
Academic Journal of Second Military Medical University
